The report “Heart Failure Drugs Market”, issued by Crystal Market Research, the market has come across substantial expansion in the recent years and is projected to grow extensively over the forecast period.
Trending Highlights of the Market:
Heart failure or medically termed as Congestive Heart Failure is a medical condition which disturbs the heart’s ability to pump blood. A few medical conditions like tapering arteries or high blood pressure with time makes the heart weak and efficiently pump blood. The global heart failure drugs market is predicted to reach USD 29.90 Billion by 2025, while soaring at a CAGR of 15.90% during the forecast period. The vigorous pipeline of drugs that are under development are the one prime driver which boosts the growth of this market. Sanctioning of new drugs from the Food and Drug Administration (FDA) is also anticipated to pay heed to the escalation of the heart failure drugs market. Besides, unhealthy lifestyle, aged population and rising awareness related to the treatment of chronic disorders are also responsible for the lucrative growth of this market. Apart from the drivers, the heart failure drugs market also ropes in a few restrains such as diagnosis rate for the disease along with the reduced awareness of the same.
Regional Insights:
The market has been segment into North America, Europe, Asia Pacific, South America and Middle East and Africa. Of which, North America is anticipated to be the leader in heart failure drugs market owing to mergers and acquisitions and novel product launches. In 2015, a US based company, Amgen Inc. acquired a Netherlands based company, DezimaPharma in order to expand its cardiovascular drug portfolio. Additionally, rising occurrence of cardiovascular diseases in Asia Pacific is predicted to back the heart failure drugs market. Also, due to frequent launch of novel heart failure preventing drugs to treat chronic diseases, European market is anticipated to experience substantial growth during the forecast period.
Competitive Gatherings:
Some of the key market players of the global heart failure drugs market are
This market is quite generic in nature. Several manufacturers of the generic drugs are delivering drugs fr any specific disease. Nonetheless, with the fresh existence of inventive drugs like EOM, is said to alter the complete dynamics of the market. Novartis AG and Astra Zeneca Plc are responsible for major share of this market on a global level. These companies are there to stay dominant during the forecast period owing to companies holding a robust pipeline. In the drug type, ARBs segment is fuelling the growth of this market owing to the decreased risk of death due to cardiac failure.
About Crystal Market Research:
Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.
Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com
Heart Failure Drugs Market By Drug Type (Beta Blockers, ARBs, ACE Inhibitors and Other Drug Types) and Distribution Channel (Hospitals, Online Pharmacies and Retail Pharmacies) - Global Industry Analysis And Forecast To 2027,
Publish Date : May 2023 Pages :145
Publish Date : May 2023 Pages :154
Publish Date : May 2023 Pages :154
Publish Date : May 2023 Pages :135
Publish Date : May 2023 Pages :105